Sopharma has completed the initial stage of a strategic pharmaceutical portfolio acquisition
As part of Sopharma’s growth strategy to expand its regional market footprint, the company has recently completed the first stage of a transaction to acquire a large pharmaceutical product portfolio, including both consumer healthcare and prescription products.
Sopharma is a leading producer and distributor of pharmaceutical products in Europe and the Commonwealth of Independent States (CIS), operating with a vertically integrated business model that spans the entire value chain. The company is present in over 30 countries, with a combined revenue of €1 billion.
The pharmaceutical product portfolio acquired includes both consumer healthcare (CHC) and prescription products across diverse therapeutic areas such as sex hormones and modulators of the genital system, urologicals and antivirals for systemic use. Comprising 68 marketing authorizations, the portfolio features 14 well-known brands across 10 of Sopharma’s key markets. The transaction will be executed in stages, with the initial payment of €40 million secured by own funds and bank financing.
The seller is a European pharmaceutical company, which is developing, manufacturing and marketing a wide range of generic and over-the-counter (OTC) products.
Oaklins’ team in Bulgaria advised Sopharma throughout the acquisition process, including transaction positioning and structuring, deal negotiations and execution.
Talk to the deal team
Related deals
EuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn moreMEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn more